Edition:
United States

Synlogic Inc (SYBX.OQ)

SYBX.OQ on NASDAQ Stock Exchange Global Market

11.50USD
1:53pm EST
Change (% chg)

$0.15 (+1.32%)
Prev Close
$11.35
Open
$11.33
Day's High
$11.88
Day's Low
$11.28
Volume
9,381
Avg. Vol
25,430
52-wk High
$23.00
52-wk Low
$8.83

Latest Key Developments (Source: Significant Developments)

Synlogic Announces Pricing Of Public Offering Of Common Stock
Wednesday, 24 Jan 2018 08:14am EST 

Jan 24 (Reuters) - Synlogic Inc ::SYNLOGIC ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.13 MILLION COMMON SHARES PRICED AT $9.75PER SHARE.  Full Article

Synlogic Announces Proposed Public Offering Of Common Stock
Tuesday, 23 Jan 2018 04:01pm EST 

Jan 23 (Reuters) - Synlogic Inc ::SYNLOGIC ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SYNLOGIC INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK​.  Full Article

Synlogic Progresses Clinical And Preclinical Pipeline And Outlines 2018 Catalysts
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Synlogic Inc ::SYNLOGIC PROGRESSES CLINICAL AND PRECLINICAL PIPELINE AND OUTLINES 2018 CATALYSTS.SYNLOGIC - EXPECTS TO PRESENT FULL CLINICAL DATA FROM FIRST IN-HUMAN STUDY OF SYNTHETIC BIOTIC MEDICINE EXPECTED IN Q1 2018.SYNLOGIC INC - IND FOR SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH LIVER DISEASE HAS BEEN CLEARED BY FDA.SYNLOGIC INC - ADDITIONAL TRIALS IN PATIENTS WITH UCD AND PKU EXPECTED TO BEGIN IN 2018.  Full Article

Synlogic, Ginkgo Bioworks To Collaborate To Discover New Living Medicines To Treat Neurological And Liver Disorders
Friday, 8 Dec 2017 06:00am EST 

Dec 8 (Reuters) - Synlogic Inc ::SYNLOGIC INC - CO, ORGANISM COMPANY GINKGO BIOWORKS TO COLLABORATE TO DISCOVER NEW LIVING MEDICINES TO TREAT NEUROLOGICAL AND LIVER DISORDERS.  Full Article

Synlogic qtrly loss per share $1.66‍​
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Synlogic Inc ::Synlogic reports third quarter 2017 financial results and recent progress.Q3 revenue $100,000.Synlogic Inc - qtrly loss per share $1.66‍​.  Full Article

Synlogic says ‍SYNB1020 was safe, well tolerated in subjects
Wednesday, 8 Nov 2017 08:00am EST 

Nov 8 (Reuters) - Synlogic Inc :Synlogic reports positive top-line phase 1 data demonstrating safety and tolerability and proof of mechanism in healthy volunteers for synb1020, a synthetic biotictm medicine for the treatment of hyperammonemia.Synlogic inc - ‍data support initiation of two phase 1b/2a studies in 2018​.Synlogic - ‍synb1020 was safe, well tolerated in subjects in multiple ascending dose cohorts.Synlogic - ‍there have been no serious adverse events, no cases of infection with bacteria in synb1020 study ​.  Full Article

Synlogic says co entered into sales agreement with Cowen And Company, LLC ​
Monday, 16 Oct 2017 04:22pm EDT 

Oct 17 (Reuters) - Synlogic Inc :Synlogic Inc - ‍on October 13, 2017 co entered into a sales agreement with Cowen And Company, LLC - SEC filing ​.Synlogic Inc - pursuant to agreement co may offer and sell, shares of its common stock, par value $0.001 per share having an offering price of up to $50 million.  Full Article

‍OrbiMed Advisors reports 8.08 pct stake in Synlogic Inc - SEC filing
Thursday, 7 Sep 2017 02:27pm EDT 

Sept 7 (Reuters) - OrbiMed Advisors LLC::‍OrbiMed Advisors LLC​ reports 8.08 percent stake in Synlogic Inc as of Aug 28 - SEC filing.  Full Article

Deerfield Management Co LP reports 5.22 pct passive stake in Synlogic as on Aug 28 - SEC Filing‍​
Wednesday, 6 Sep 2017 06:25am EDT 

Sept 6 (Reuters) - Synlogic Inc :Deerfield Management Company, L.P. reports 5.22 percent passive stake in Synlogic Inc as on August 28, 2017 - SEC Filing‍​.  Full Article

Synlogic and Mirna therapeutics agree to merger
Tuesday, 16 May 2017 06:30am EDT 

May 16 (Reuters) - Mirna Therapeutics Inc :Synlogic and Mirna Therapeutics agree to merger.Mirna Therapeutics Inc says first clinical trial for lead Synlogic product candidate anticipated to start mid-2017.Says Synlogic closes $42 million of series C preferred stock financing by leading biotechnology investors.Mirna Therapeutics Inc - combined company well-capitalized with approximately $82 million in cash expected at closing from merger and series C.Mirna Therapeutics Inc - following merger, current Synlogic shareholders are expected to own approximately 83 percent of combined company.Says by mid-2017, Synlogic plans to initiate a phase 1 healthy volunteers study for its lead candidate, SYNB1020.Mirna Therapeutics Inc - transaction has been approved by board of directors of both companies.Mirna Therapeutics Inc - Synlogic will merge with a wholly owned subsidiary of Mirna in an all-stock transaction.Mirna Therapeutics Inc - following merger, Jose Carlos Gutierrez-Ramos, Synlogic's chief executive officer will become chief executive officer of merged company.Says following merger, current Mirna stockholders will own approximately 17 percent of combined company.Mirna Therapeutics Inc - merged company will continue under Synlogic name.Mirna Therapeutics Inc - following merger, board will be comprised of seven directors, including two directors currently serving on Mirna's board.  Full Article